BioAtla (BCAB) Return on Capital Employed (2021 - 2026)
BioAtla (BCAB) posted quarterly Return on Capital Employed of 501.5% for Q4 2025, up 67431.0% year-over-year from N/an in Q4 2024, and up 126.74% quarter-over-quarter from 1875.63% in Q3 2025.
BioAtla (BCAB) Return on Capital Employed (2021 - 2026) Analysis & Trends
BioAtla's Return on Capital Employed history runs 5 years deep, the most recent figure standing at 501.5% for Q4 2025.
- In Q4 2025, Return on Capital Employed rose 67431.0% year-over-year to 501.5%; the TTM figure through Dec 2025 stood at 501.5% (up 67431.0% YoY), while the FY2025 annual figure was 922.1%, down 81869.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 501.5%, up from 1875.63% in the prior quarter.
- The five-year high for Return on Capital Employed was 501.5% in Q4 2025, with the low at 1875.63% in Q3 2025.
- The 5-year median for Return on Capital Employed is 67.98% (2023), against an average of 170.05%.
- Peak annual rise in Return on Capital Employed reached 67431 bps in 2025, while the deepest fall reached 168806 bps in 2025.
- BioAtla's Return on Capital Employed stood at 39.17% in 2021, then tumbled by 50 bps to 58.68% in 2022, then plunged by 106 bps to 121.02% in 2023, then slumped by 43 bps to 172.81% in 2024, then jumped by 390 bps to 501.5% in 2025.
- Business Quant data shows BCAB's Return on Capital Employed at 501.5% in Q4 2025, 1875.63% in Q3 2025, and 395.88% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.51 Bn | 78.51 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.74 Bn | 60.56 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.39 Bn | 54.26 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.24 Bn | 37.15 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.78 Bn | 28.47 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.22 Bn | 26.39 Bn | - | 7.88% |
| 10 | BioAtla | 5.41 Mn | 5.41 Mn | - | 199.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 199.57% |
| Mar 31, 2026 | 357.47% |
| Dec 31, 2025 | 501.50% |
| Sep 30, 2025 | -1,875.63% |
| Jun 30, 2025 | -395.88% |
| Mar 31, 2025 | -228.62% |
| Dec 31, 2024 | -172.81% |
| Sep 30, 2024 | -187.57% |
| Jun 30, 2024 | -178.97% |
| Mar 31, 2024 | -147.02% |
| Dec 31, 2023 | -121.02% |
| Sep 30, 2023 | -99.86% |
| Jun 30, 2023 | -76.29% |
| Mar 31, 2023 | -59.68% |
| Dec 31, 2022 | -58.68% |
| Sep 30, 2022 | -58.07% |
| Jun 30, 2022 | -51.17% |
| Mar 31, 2022 | -45.26% |
| Dec 31, 2021 | -39.17% |
| Sep 30, 2021 | -44.28% |